Uppsala Monitoring Centre

who-umc.org

Uppsala Monitoring Centre is an independent, non-profit foundation and a centre for international service and scientific research in the field of pharmacovigilance.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

MERCK DRIVES NEW INNOVATION & ADDS CAPACITY TO ADVANCE NEXT GENERATION ANTIBODY-DRUG CONJUGATE (ADC) THERAPIES

Merck | October 29, 2021

news image

Merck, a leading science and technology company, today announced that its Life Science business sector has launched new technology and expanded capacity to advance ADC therapies. These initiatives underscore Merck's continued investment in novel modalities and support the company's efforts to double its ADC and high-potent active pharmaceutical ingredient (HPAPI) capacity in the near future. "ADCs have experienced remarkable growth, with commerci...

Read More

Pharmacy Market

VIPERGEN AND LEO PHARMA PARTNER FOR DNA ENCODED LIBRARY (DEL)-BASED DRUG DISCOVERY FOR DERMATOLOGY INDICATIONS

Vipergen | June 20, 2022

news image

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library technologies, announced a multi-target drug discovery partnership with LEO Pharma focused on novel treatments for dermatology indications. Under the terms of the agreement, Vipergen will apply its high-fidelity DNA-encoded library (DEL) screening technologies, including its new in-living-cell DEL platform, to discover novel small-molecule compounds that bind to selected LEO Pharma t...

Read More

CNS PHARMACEUTICALS ANNOUNCES US DRUG MANUFACTURING MILESTONES

CNS Pharmaceuticals | September 03, 2020

news image

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today provides an update on progress for the U.S. manufacturing of Berubicin, the Company's lead drug candidate, in preparation for upcoming clinical trials. As previously announced, the Company implemented a dual-track drug product manufacturing strategy and eng...

Read More

Business Insights

ELEMENT FURTHER EXPANDS ITS LIFE SCIENCES TESTING BUSINESS WITH ADDITIONAL PHARMACEUTICAL AND BIOTECH TESTING CAPABILITIES IN NORTH AMERICA AND EUROPE

Element Materials Technology | January 15, 2022

news image

Element Materials Technology (Element) completed its sixth life sciences-focused acquisition of 2021, with the formal completion of the acquisition of JMI Laboratories. Element has now built out its expertise and capability for pharmaceutical and biopharmaceutical customers, expanding to a team of more than 1,000 experts in 23 facilities across North America and Europe. This significant step change in pharmaceutical and medical testing capabilities from Element forms part of its b...

Read More
news image

Pharma Tech

MERCK DRIVES NEW INNOVATION & ADDS CAPACITY TO ADVANCE NEXT GENERATION ANTIBODY-DRUG CONJUGATE (ADC) THERAPIES

Merck | October 29, 2021

Merck, a leading science and technology company, today announced that its Life Science business sector has launched new technology and expanded capacity to advance ADC therapies. These initiatives underscore Merck's continued investment in novel modalities and support the company's efforts to double its ADC and high-potent active pharmaceutical ingredient (HPAPI) capacity in the near future. "ADCs have experienced remarkable growth, with commerci...

Read More
news image

Pharmacy Market

VIPERGEN AND LEO PHARMA PARTNER FOR DNA ENCODED LIBRARY (DEL)-BASED DRUG DISCOVERY FOR DERMATOLOGY INDICATIONS

Vipergen | June 20, 2022

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library technologies, announced a multi-target drug discovery partnership with LEO Pharma focused on novel treatments for dermatology indications. Under the terms of the agreement, Vipergen will apply its high-fidelity DNA-encoded library (DEL) screening technologies, including its new in-living-cell DEL platform, to discover novel small-molecule compounds that bind to selected LEO Pharma t...

Read More
news image

CNS PHARMACEUTICALS ANNOUNCES US DRUG MANUFACTURING MILESTONES

CNS Pharmaceuticals | September 03, 2020

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today provides an update on progress for the U.S. manufacturing of Berubicin, the Company's lead drug candidate, in preparation for upcoming clinical trials. As previously announced, the Company implemented a dual-track drug product manufacturing strategy and eng...

Read More
news image

Business Insights

ELEMENT FURTHER EXPANDS ITS LIFE SCIENCES TESTING BUSINESS WITH ADDITIONAL PHARMACEUTICAL AND BIOTECH TESTING CAPABILITIES IN NORTH AMERICA AND EUROPE

Element Materials Technology | January 15, 2022

Element Materials Technology (Element) completed its sixth life sciences-focused acquisition of 2021, with the formal completion of the acquisition of JMI Laboratories. Element has now built out its expertise and capability for pharmaceutical and biopharmaceutical customers, expanding to a team of more than 1,000 experts in 23 facilities across North America and Europe. This significant step change in pharmaceutical and medical testing capabilities from Element forms part of its b...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us